Fulgent Genetics (FLGT) vs Illumina (ILMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Illumina (ILMN) has outperformed Fulgent Genetics (FLGT) over the past year, gaining 170.6% versus a loss of 8.8%. Over five years, ILMN leads with a -33.7% price change compared with -73.3% for FLGT. Illumina is the larger company by market cap ($39.95 billion vs $572.9 million), about 69.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FLGT | ILMN |
|---|---|---|
| Share price | $20.82 | $264.57 |
| Market cap | $572.87M | $39.95B |
| 1-day change | +1.22% | -1.19% |
| YTD return | -20.75% | +101.72% |
| 1-year return | -8.80% | +170.58% |
| 5-year return | -73.31% | -33.65% |
| P/E ratio (TTM) | — | 49.36 |
| Forward P/E | — | 43.24 |
| EPS (TTM) | $-2.82 | $5.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $4.34B |
| Revenue growth (YoY) | — | -0.66% |
| Net income (latest FY) | — | $850.00M |
| Gross margin | — | 66.08% |
| Operating margin | — | 18.58% |
| Net margin | — | 19.57% |
| 52-week high | $31.04 | $309.35 |
| 52-week low | $13.46 | $88.00 |
| Distance from 52-week high | -32.93% | -14.48% |
| Analyst consensus | none | buy |
| Avg. price target upside | -8.74% | -12.25% |
| Average volume | 301.04K | 2.69M |
| Shares outstanding | 27.52M | 151.00M |
| Employees | 1,315 | 8,600 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Illumina is about 69.7 times larger than Fulgent Genetics by market value ($39.95B vs $572.87M).
- ILMN has outperformed FLGT by 179.4 percentage points over the past year.
About Fulgent Genetics
FLGT stock →Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
Healthcare · Diagnostics & Research · 1,315 employees
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Healthcare · Diagnostics & Research · 8,600 employees
FLGT vs ILMN FAQ
Which is bigger, Fulgent Genetics or Illumina?
Illumina (ILMN) is larger, with a market capitalization of $39.95B compared with $572.87M for Fulgent Genetics (FLGT).
Which stock has performed better over the past year, FLGT or ILMN?
ILMN returned +170.58% over the past 12 months, compared with -8.80% for FLGT (price return, excluding dividends). Past performance does not predict future results.
Are Fulgent Genetics and Illumina in the same industry?
Yes. Both are classified in the Diagnostics & Research industry within the Healthcare sector.